Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck/MedImmune

Executive Summary

Collaboration on MEDI-488 anti-HIV monoclonal antibody will continue following a review that began in January of the available data ("The Pink Sheet" Jan. 11, T&G-8), Gaithersburg, Md.-based MedImmune reports March 4. The companies have modified their autumn 1991 three-year deal: Merck will fund internal development of MEDI-488 but defer MedImmune research on other anti-HIV MAbs at least until after Phase I trials of MEDI-488.
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS022253

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel